Glioblastoma has remained one of the toughest cancers to treat, resisting even the latest advances in immunotherapy. But new ...

Glioblastoma has long resisted treatment, but scientists may have found a breakthrough by leveraging the body's own ...

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

The novel therapy is anticipated to function like PD-1/PD-L1 blockade with significant clinical efficacy results in ...

The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...

Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...

ELF4, a transcription factor belonging to the ETS family, has emerged as a pivotal regulator in cell differentiation, immune system function, and cancer progression. This newly published review ...

While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...

Karnataka: Shilpa Biologicals Pvt Ltd., a fully owned subsidiary of Shilpa Medicare Limited has signed an exclusive ...

Glioblastoma has remained one of the toughest cancers to treat, but new research suggests that suppressing a protein (ZNF638) ...